Abstract
Accumulation of hyaluronan (HA) in pericellular stroma and carcinoma cells is predictive of unfavorable patient prognosis in many epithelial cancers. However, it is not known whether the HA originates from carcinoma or stromal cells, or whether increased expression of hyaluronan synthase proteins (HAS1–3) contributes to HA accumulation. In this study, localization and expression of HAS1–3 were evaluated immunohistochemically in 278 cases of human breast cancer, and correlated with prognostic factors and patient outcome. Both carcinoma cells and stromal cells were HAS-positive. In carcinoma cells, HAS1 and HA stainings correlated with each other, and HAS1 associated with estrogen receptor negativity, HER2 positivity, high relapse rate, and short overall survival. In stromal cells, the staining levels of all HAS isoforms correlated with the stromal HA staining, stromal cell CD44, high relapse rate, and short overall survival of the patients. In addition, expression levels of stromal HAS1 and HAS2 were related to obesity, large tumor size, lymph node positivity, and estrogen receptor negativity. Thus, stromal HAS1 and HAS3 were independent prognostic factors in the multivariate analysis. The data suggest that increased levels of HAS enzymes contribute to the accumulation of HA in breast cancer, and that HA is synthesized in carcinoma cells and stromal cells. The study also indicates that HAS enzyme levels are related to tumor aggressiveness and poor patient outcome representing potential targets for therapy.
Similar content being viewed by others
Abbreviations
- HA:
-
Hyaluronan
- Has, HAS:
-
Hyaluronan synthase gene and protein
- bHABC:
-
Biotinylated hyaluronan binding complex
- HR:
-
Hazard ratio
- TSG-6:
-
Tumor necrosis factor alpha stimulated gene-6
- IαI:
-
Inter alpha inhibitor
- UDP:
-
Uridine diphosphate
- RAR:
-
Retinoic acid receptor
- STAT:
-
Signal transducer and activator of transcription
- NF-kB:
-
Nuclear factor kappa-light-chain-enhancer of activated B cells
- CREB:
-
cAMP response element binding protein
- CISH:
-
Chromogenic in situ hybridization
- BMI:
-
Body mass index
- GlcUA:
-
Glucuronic acid
- GlcNAc:
-
N-acetyl-glucosamine
References
Tammi R, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi M (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18:288–295
Auvinen P, Tammi R, Parkkinen J, Tammi M, Ågren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156:529–536
Weigel P, DeAngelis P (2007) Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J Biol Chem 282:36777–36781
Camenisch T, Spicer A, Brehm-Gibson T, Biesterfeldt J, Augustine M, Calabro A Jr, Kubalak S, Klewer S, McDonald J (2000) Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 106:349–360
Tammi R, Passi A, Rilla K, Karousou E, Vigetti D, Makkonen K, Tammi M (2011) Transcriptional and post-translational regulation of hyaluronan synthesis. FEBS J 278:1419–1428
Tammi R, MacCallum D, Hascall V, Pienimäki J, Hyttinen M, Tammi M (1998) Hyaluronan bound to CD44 on keratinocytes is displaced by hyaluronan decasaccharides and not hexasaccharides. J Biol Chem 273:28878–28888
Evanko S, Tammi M, Tammi R, Wight T (2007) Hyaluronan-dependent pericellular matrix. Adv Drug Deliv Rev 59:1351–1365
Rilla K, Siiskonen H, Spicer A, Hyttinen J, Tammi M, Tammi R (2005) Plasma membrane residence of hyaluronan synthase is coupled to its enzymatic activity. J Biol Chem 280:31890–31897
Kultti A, Pasonen-Seppänen S, Jauhiainen M, Rilla KJ, Kärnä R, Pyöriä E, Tammi R, Tammi M (2009) 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315:1914–1923
Kramer M, Escudero D, Lokeshwar S, Golshani R, Ekwenna O, Acosta K, Merseburger A, Soloway M, Lokeshwar V (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117:1197–1209
Chi A, Shirodkar S, Escudero D, Ekwenna O, Yates T, Ayyathurai R, Garcia-Roig M, Gahan J, Manoharan M, Bird V, Lokeshwar V (2012) Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer 118:2394–2402
Yamada Y, Itano N, Narimatsu H, Kudo T, Morozumi K, Hirohashi S, Ochiai A, Ueda M, Kimata K (2004) Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer. Clin Exp Metastasis 21:57–63
Yabushita H, Noguchi M, Kishida T, Fusano K, Noguchi Y, Itano N, Kimata K, Noguchi M (2004) Hyaluronan synthase expression in ovarian cancer. Oncol Rep 12:739–743
Nykopp T, Rilla K, Tammi MI, Tammi RH, Sironen R, Hämäläinen K, Kosma VM, Heinonen S, Anttila M (2010) Hyaluronan synthases (HAS1–3) and hyaluronidases (HYAL1–2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. BMC Cancer 10:512
Udabage L, Brownlee G, Waltham M, Blick T, Walker E, Heldin P, Nilsson S, Thompson E, Brown T (2005) Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 65:6139–6150
Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, Xing F, Liu W, Pandey P, Fukuda K, Modur V, Ghosh A, Wilber A, Watabe K (2012) Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 72:537–547
Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E, Tammi M (2013) Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 132:531–539
Törrönen K, Nikunen K, Kärnä R, Tammi M, Tammi R, Rilla K (2013) Tissue distribution and subcellular localization of hyaluronan synthase isoenzymes. Histochem Cell Biol. doi:10.1007/s00418-013-1143-4
Tammi R, Ågren U, Tuhkanen A, Tammi M (1994) Hyaluronan metabolism in skin. Prog Histochem Cytochem 29:1–81
McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235
Bharadwaj A, Kovar J, Loughman E, Elowsky C, Oakley G, Simpson M (2009) Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 174:1027–1036
Itano N, Kimata K (2008) Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol 18:268–274
Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, Hamaguchi M, Kimata K (2004) Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 279:18679–18687
Ichikawa T, Itano N, Sawai T, Kimata K, Koganehira Y, Saida T, Taniguchi S (1999) Increased synthesis of hyaluronate enhances motility of human melanoma cells. J Invest Dermatol 113:935–939
Karousou E, Kamiryo M, Skandalis SS, Ruusala A, Asteriou T, Passi A, Yamashita H, Hellman U, Heldin CH, Heldin P (2010) The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination. J Biol Chem 285:23647–23654
Petersen O, Nielsen H, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell M, Ronnov-Jessen L (2003) Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 162:391–402
Zoltan-Jones A, Huang L, Ghatak S, Toole B (2003) Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 278:45801–45810
Porsch H, Bernert B, Mehic M, Theocharis A, Heldin C, Heldin P (2012) Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 32(37):4355–4365
Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, Kannagi R, Kimata K, Taniguchi S, Itano N (2007) Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 170:1086–1099
Rilla K, Oikari S, Jokela TA, Hyttinen J, Kärnä R, Tammi R, Tammi M (2013) Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3. J Biol Chem 288:5973–5983
Vigetti D, Deleonibus S, Moretto P, Karousou E, Viola M, Bartolini B, Hascall V, Tammi M, De Luca G, Passi A (2012) Role of UDP-N-acetylglucosamine (GlcNAc) and O-GlcNAcylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis. J Biol Chem 287:35544–35555
van den Brandt P, Spiegelman D, Yaun S, Adami H, Beeson L, Folsom A, Fraser G, Goldbohm R, Graham S, Kushi L, Marshall J, Miller A, Rohan T, Smith-Warner S, Speizer F, Willett W, Wolk A, Hunter D (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514–527
Contiero P, Berrino F, Tagliabue G, Mastroianni A, Di Mauro M, Fabiano S, Annulli M, Muti P (2013) Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study. Breast Cancer Res Treat 138:951–959
Varadi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, Besznyak I Jr, Jakab F, Baranyai Z, Szollosi J, Nagy P (2012) Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem 60:567–575
Hascall V, Majors A, De La Motte C, Evanko S, Wang A, Drazba JA, Strong S, Wight T (2004) Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta 1673:3–12
Toole B (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–539
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Baek J, Jin Q, Ensor J, Boulbes D, Esteva F (2011) Serum CD44 levels and overall survival in patients with HER2-positive breast cancer. Breast Cancer Res Treat 130:1029–1036
Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, Kozawa E, Futamura N, Ishiguro N (2012) Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 130:454–466
Acknowledgments
This study has been supported by Special Government Funding (EVO) of Kuopio University Hospital (PA, VMK, MT), Cancer Center of University of Eastern Finland (PA, VMK, MT, RT), Sigrid Juselius Foundation (RT, MT), Northern Savo Cancer Foundation (KR).We thank Helena Kemiläinen, Eija Rahunen, and Kari Kotikumpu for their assistance in the laboratory.
Conflict of interest
The authors declare that they have no conflict of interest, neither financial nor personal.
Ethical standards
The permission for this study was provided by the ethics committee of University of Eastern Finland and by the national authority—VALVIRA.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Auvinen, P., Rilla, K., Tumelius, R. et al. Hyaluronan synthases (HAS1–3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat 143, 277–286 (2014). https://doi.org/10.1007/s10549-013-2804-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-013-2804-7